|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF445 |
Gene summary for ZNF445 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF445 | Gene ID | 353274 |
| Gene name | zinc finger protein 445 | |
| Gene Alias | ZFP445 | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P59923 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 353274 | ZNF445 | HCC1_Meng | Human | Liver | HCC | 5.26e-51 | 7.60e-02 | 0.0246 |
| 353274 | ZNF445 | HCC2_Meng | Human | Liver | HCC | 2.03e-04 | -2.21e-02 | 0.0107 |
| 353274 | ZNF445 | HCC1 | Human | Liver | HCC | 1.93e-11 | 2.84e+00 | 0.5336 |
| 353274 | ZNF445 | HCC2 | Human | Liver | HCC | 9.57e-21 | 3.12e+00 | 0.5341 |
| 353274 | ZNF445 | HCC5 | Human | Liver | HCC | 6.16e-11 | 2.86e+00 | 0.4932 |
| 353274 | ZNF445 | S014 | Human | Liver | HCC | 3.78e-04 | 3.30e-01 | 0.2254 |
| 353274 | ZNF445 | S015 | Human | Liver | HCC | 9.35e-04 | 3.78e-01 | 0.2375 |
| 353274 | ZNF445 | S016 | Human | Liver | HCC | 2.28e-04 | 3.20e-01 | 0.2243 |
| 353274 | ZNF445 | S028 | Human | Liver | HCC | 5.29e-10 | 5.32e-01 | 0.2503 |
| 353274 | ZNF445 | S029 | Human | Liver | HCC | 1.86e-05 | 5.11e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF445 | TH1 | Lung | Healthy | NIT2,ACYP1,C1orf122, etc. | 4.33e-03 |  |
| ZNF445 | NUER | Prostate | BPH | SLC9A9,IGLC7,HSD17B13, etc. | 4.44e-16 |  |
| ZNF445 | URO | Prostate | BPH | SLC9A9,IGLC7,HSD17B13, etc. | 7.07e-04 | |
| ZNF445 | SMC | Skin | Healthy | PPM1B,SMIM19,ZNF668, etc. | 1.16e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF445 | SNV | Missense_Mutation | novel | c.795N>T | p.Glu265Asp | p.E265D | P59923 | protein_coding | deleterious(0.01) | probably_damaging(0.926) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF445 | SNV | Missense_Mutation | rs754731745 | c.185N>A | p.Arg62His | p.R62H | P59923 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A0AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF445 | SNV | Missense_Mutation | c.2420G>T | p.Arg807Leu | p.R807L | P59923 | protein_coding | deleterious(0.03) | possibly_damaging(0.892) | TCGA-AO-A1KT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD | |
| ZNF445 | SNV | Missense_Mutation | c.1274C>T | p.Ser425Leu | p.S425L | P59923 | protein_coding | deleterious(0.02) | benign(0.254) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| ZNF445 | SNV | Missense_Mutation | c.1393N>C | p.Asp465His | p.D465H | P59923 | protein_coding | tolerated(0.15) | benign(0.359) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| ZNF445 | SNV | Missense_Mutation | novel | c.1986N>A | p.Phe662Leu | p.F662L | P59923 | protein_coding | tolerated(0.2) | benign(0) | TCGA-OL-A66L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF445 | insertion | Frame_Shift_Ins | novel | c.1914_1915insGG | p.Asn639GlyfsTer7 | p.N639Gfs*7 | P59923 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ZNF445 | insertion | In_Frame_Ins | novel | c.1913_1914insCCATACACCAGGCGCTGGTGTGTTTGCCAGAGACCCAGC | p.Ser638_Asn639insHisThrProGlyAlaGlyValPheAlaArgAspProAla | p.S638_N639insHTPGAGVFARDPA | P59923 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ZNF445 | insertion | Frame_Shift_Ins | novel | c.2788_2789insGATTCTGT | p.Ala930GlyfsTer13 | p.A930Gfs*13 | P59923 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ZNF445 | SNV | Missense_Mutation | c.1039N>A | p.Glu347Lys | p.E347K | P59923 | protein_coding | tolerated(0.1) | benign(0.093) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |